Disclosure: Dr. Sebba has received financial support in the form of research grants and lecture honoraria from Hoffmann-La Roche Inc. Cells producing interleukin-6 (IL-6) and the actions of IL-6 ...

The empirical dietary inflammatory pattern (EDIP) score, used in the study to measure the inflammatory potential of patients' ...

Bimekizumab demonstrated a favorable safety profile for the long-term treatment of axSpA and PsA, with rates of TEAEs remaining stable over time.

Insilico plans late-stage trials for rentosertib following positive mid-stage safety and efficacy data for idiopathic ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

This five-year analysis of the C-144-01 trial represents unprecedented durability and duration of follow-up in advanced melanoma patients previously treated with anti-PD-1 and targeted therapy, where ...

This study presents an important finding on the role of GATA4 in aging and OA-associated cartilage pathology. The evidence supporting the conclusions is compelling, with rigorous in vitro and in vivo ...

Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.

Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in HR+/HER2– advanced breast cancer. Dr. Debu Tripathy breaks down the FDA approval ...

Truqap can be used in patients whose disease has progressed despite prior endocrine therapy with a CDK 4/6 inhibitor and an aromatase inhibitor, according to a newly published guidance document.

In NMOSD, Soliris is also facing competition from Horizon Therapeutics' CD19-directed cytolytic antibody Uplizna (inebilizumab) and Roche's IL-6 inhibitor Enspryng (satralizumab). In the first ...